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Abstract 
The present overview focuses on evidence of smoking cessation approaches in oncology settings with the aim to 
provide health personnel a critical perspective on how to help their patients. This narrative review is structured in two 
main sections: the first one describes the psycho-cognitive variables involved in the decision to continue smoking 
after a cancer diagnosis and during the treatment; the second section relates methods and tools may be recom-
mended, being evidence-based, to support smoking cessation in oncology settings. Active smoking increases not 
only susceptibility to common cancers in the general population, but also increases disease severity and comor-
bidities in cancer patients. Nowadays, scientific evidence has identified many strategies to give up smoking, but a 
lack of knowledge exists for treatment of nicotine dependence in the cancer population. Health personnel is often 
ambiguous when approaching the problem, while their contribution is essential in guiding patients towards healthier 
choices. We argue that smoking treatments for cancer patients deserve more attention and that clinical features, 
individual characteristics and needs of the patient should be assessed in order to increase the attempts success rate. 
Health personnel that daily work and interact with cancer patients and their caregivers have a fundamental role in the 
promotion of the health changing. For this reason, it is important that they have adequate knowledge and resources 
in order to support cancer patients to stop tobacco cigarette smoking and promoting and healthier lifestyle.
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Background
Tobacco cigarette smoking is the leading cause of pre-
ventable death in the world. In 2011 the World Health 
Organization (WHO) declared that smoking caused six 
million deaths annually, and in 2030 it will kill eight mil-
lion people each year (WHO 2011).
Bio-physiological evidence suggests that smoking is the 
main cause of respiratory diseases (e.g. chronic obstruc-
tive pulmonary disease and pulmonary emphysema), 
cardiovascular events (e.g. aneurysm and stroke) and 
many cancers (esophagus, larynx, oral cavity, bladder, 
stomach, kidney, squamous cell carcinoma of the cervix; 
Ehlers and Bronars 2012). Statistical figures confirm that 
tobacco dependence causes 30 % of all cancers and 80 % 
of deaths from neck, head, and lung cancer (Morgan et al. 
2011). Particularly, about 90  % of lung cancer is assign-
able to tobacco cigarette smoking (Nayan et al. 2011).
Despite this evidence, many patients still smoke regu-
larly after a diagnosis of cancer. In 2013 the American 
National Cancer Institute published a scientific state-
ment on treating tobacco dependence in the cancer pop-
ulation. The report highlighted that 50  % of individuals 
with cancer who smoke before diagnosis continue smok-
ing during treatment, and that, for patients who gave up 
smoking, the relapse rate was very high (Toll et al. 2013). 
Data showed that 23–35  % of head and neck cancer 
patients, and 13–20 % of lung cancer patients who were 
smoking before their diagnosis, continued to smoke after 
the diagnosis and during treatment itself (Nayan et  al. 
2011), while de Bruin-Visser et  al. (2012) reported that 
35–72 % of head and neck cancer patients’ smoke despite 
the diagnosis.
Also women with breast cancer are reported as con-
tinuing to smoke after the diagnosis (Land et al. 2011). In 
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this study, cigarette smoking was found to be negatively 
correlated to treatment adherence.
Continuing to smoke after a cancer diagnosis may 
produce several adverse health outcomes (Cropley et al. 
2008). Epidemiological research shows that tobacco 
cigarette smoking decreases survival time (Gritz and 
Demark-Wahnefried 2009), it increases the risk of second 
primary malignancies (Zevallos et al. 2009) and the like-
lihood of recurrences (Schnoll et al. 2004). For instance, 
smokers with Hodgkin’s disease have an increased risk 
of a second primary lung cancer (McBride and Ostroff 
2003) when compared to never-smokers under the same 
conditions. Also, it has been shown that tobacco use 
decreases survival rate after hematopoietic stem cell 
transplantation (Marks et  al. 2009; Ehlers et  al. 2011). 
Furthermore, cigarette smoking decreases treatment effi-
cacy (Waller et al. 2010) and increases complications and 
side-effects (Schnoll et al. 2004) for many types of cancer. 
In this regard, clinical studies revealed that in head and 
neck (Blalock et  al. 2011), and lung (Zhang et  al. 2009) 
cancer patients, smoking behavior decreases the efficacy 
of radiotherapy, while increasing drug toxicity and side-
effects (such as impaired pulmonary function, nausea, 
and dry mouth) (Nayan et al. 2011). Daniel et al. (2009) 
showed that patients with lung cancer who did not dis-
continue smoking reported more pain during the disease 
progression than former smokers and non-smokers. Sim-
ilar concerns have also been observed in patients with 
bladder and renal cancer (Videtic et  al. 2003). Finally, 
smoker patients have a high risk of developing postop-
erative complications than do non-smoker patients, for 
example showing poor wound healing (Thomsen et  al. 
2010a, b; see Table 1). 
In spite of the evidence, there is still a significant lack 
of smoking treatment research for oncology patients. A 
cancer diagnosis may provide a useful teachable moment 
(Gritz 1991) for quitting smoking, but this chance is fre-
quently undervalued by the healthcare system (Weaver 
et al. 2012).
A number of studies reported that oncology patients 
actually try to give up, but they generally make their 
attempts without help. For example, a recent study by 
Vaidya et  al. (2014) reported that many patients keep 
on smoking even after a diagnosis of lung cancer. Khul-
lar et  al. (2013) stated that patients do not receive 
enough support from physicians. Indeed, 50  % of phy-
sicians do not regularly talk about antismoking strate-
gies with patients. Cooley et  al. (2009) have shown that 
despite the a broad diffusion of information about the 
benefits of smoking cessation after a lung cancer diag-
nosis, few patients actually succeed in their attempt and 
find little support from health personnel pre- and post-
surgery. Confirming this evidence, a large online survey 
conducted by Warren et  al. (2013) in 1507 members of 
the International Association for the Study of Lung Can-
cer revealed that though most physicians believes smok-
ing cessation to be an important issues for their patients, 
only 40 % discuss quit options and only 39 % actively sup-
port patients.
Generally, oncologists provide wide-ranging sugges-
tions regarding smoking-related risks, but they do not 
give detailed information regarding available treatments, 
nor do they offer a support program during the whole 
therapeutic journey (Weaver et  al. 2012). This view has 
been recently supported by a qualitative study conducted 
by Champassak et  al. (2014), which showed, through a 
series of interview, the mismatch between the physicians’ 
believe of the importance of smoking cessation programs 
and the actual behavior during visits. Indeed, physi-
cians report a lack of confidence in their smoking cessa-
tion counseling ability. Furthermore, physicians rarely 
reported to use recommended strategies, even when 
they are acknowledged. Another particular case is that of 
hematologic cancers. Indeed, in a hematological oncol-
ogy department for patients undergoing hematopoietic 
stem cell transplantation, quitting is a priority, since 
studies exist (Chang et al. 2004) associating smoking with 
worse outcomes. Despite this, Ehlers et al. (2011) showed 
Table 1 Summary of  the benefits related to  smoking ces-
sation during and after cancer treatment
Benefits of smoking cessation post-diagnosis
Physical dimension
 Decreasing the side-effects of the therapy
 Increasing treatment efficacy
 Overcoming chemo resistance
 Improving outcome of the surgery
 Counteracting tumor progression
 Reducing fatigue
 Increasing activity level
 Reducing the likelihood of developing second primary malignancies
 Avoiding recurrence
 Improving survival rate
Psychological dimension
 Improving cognitive process
 Enhancing psychological well-being
 Increasing self-esteem
 Reducing blame (when cancer is smoking-related)
 Supporting self-efficacy health behavior-related
 Improving mood
Health behaviors
 Supporting healthy lifestyle
 Promoting preventive behavior
 Enhancing general quality of life of the patients (e.g. quality of sleep)
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that many hematologic patients continue to smoke after 
diagnosis. Also, authors noted the lack of studies address-
ing the issue of helping patients quit smoking (Ehlers and 
Bronars 2012), and the training of healthcare profession-
als in the management of the smoker patient.
Starting from this theoretical background, the main 
aim of this brief review is to sketch an overview of the 
available options to approach smoking dependence in an 
oncology setting. In order to achieve this goal, the paper 
has been structured into three conceptual sections. The 
first section describes the role of the psycho-cognitive 
processes that reinforce cigarette smoking behavior in 
patients with cancer. The second section discusses the 
cognitive-behavioral interventions and smoking cessa-
tion aids, focusing both on advantages and disadvan-
tages, in in-patient and out-patient settings. Finally, we 
offer some suggestions for health professionals to over-
come roadblocks and to improve the smoking cessation 
success rate in cancer patients.
Method
This narrative review is structured in two main sec-
tions: the first one describes the psycho-cognitive vari-
ables involved in the decision to continue smoking after 
a cancer diagnosis and during the treatment; the second 
section relates methods and tools may be recommended, 
being evidence-based, to support smoking cessation in 
oncology settings.
Searches were conducted through MEDLINE, 
EMBASE, PubMed, SCOPUS, PsycINFO and Google 
Scholar. The following keywords or combinations were 
used: cigarettes smoking, cancer, oncology patient, 
oncology setting, smoking cessation, antismoking treat-
ment, nicotine dependence, nicotine replace treatment, 
varenicline, bupropion, electronic cigarettes, smoking 
cessation counseling.
In the first section, we considered papers from 1990 to 
May 2016, using previous systematic reviews, national 
and international reports, and empirical studies. While 
in the second section, we included only controlled trials 
studies from 1990 to May 2016.
Articles in languages other than English and letters 
and editorials were excluded. The initial search identi-
fied 763 articles. An initial review of the titles abstracts 
of these articles by 2 of the authors identified 133 articles 
that were potentially relevant to the current review. The 
abstracts of these articles were then evaluated against the 
inclusion criteria by the authors, resulting in 35 articles 
being identified as eligible for inclusion, with an addi-
tional 6 articles identified during manuscript preparation, 
for a total of 41 articles. This review provides a narrative 
synthesis of the findings from previous key reviews and 
empirical studies identified in the literature search.
Inclusion and exclusion criteria section 1:
We included article assessing the behavioral, psychologi-
cal and cognitive characteristic of adult smokers after a 
diagnosis of cancer, including nicotine dependence level 
and motivation to quit. We also reviewed paper (review 
or empirical studies) that evaluated the rate of patients 
that continue smoking after a cancer diagnosis. We 
excluded editorial, opinion papers, letters and articles 
related to adult smokers after childhood cancer.
Inclusion and exclusion criteria for section 2:
We included prospective controlled studies about adults 
patients after a diagnosis of cancer during their clinical 
treatment, measuring the effectiveness of a smoking ces-
sation treatment on smokers who received a diagnosis of 
cancer and describing the smoking cessation methods 
used, including the type of provider and the clinical set-
ting. We considered studies that specify the cancer sites 
of patients and stage. We excluded studies on mixed pop-
ulation (cancer patients and other diseases), cohort stud-
ies as well as surveys.
Cognitive profile of the cancer patient who smokes
Westmaas et  al. (2015), in a large prospective study 
on a US cohort (including more than 12,000 smokers) 
showed that a cancer diagnosis is associated with sig-
nificantly higher rates of quitting smoking within both 2 
and 4 years of the diagnosis. Almost one in three smokers 
who received a cancer diagnosis in their study had quit 
smoking within 2 years, compared with fewer than one in 
five smokers who had never received a cancer diagnosis. 
Moreover, the greater quitting rate among cancer-diag-
nosed smokers is maintained at 4 years. Interestingly, also 
non-smoking related diagnosis affected patients’ smoking 
habits. However, even though a diagnosis of cancer seem 
to be a true teachable moment, not all patients actually 
change their behavior. In particular, patients with preex-
isting chronic conditions that are linked to smoking (e.g. 
chronic obstructive pulmonary disease) have low rates of 
quitting after cancer diagnosis. Coherently, Burris et  al. 
(2015) aggregating data across 131 studies on head and 
neck cancer patients, found that about 50 % of smokers 
patients continue smoking after diagnosis, while previous 
studies reported a range of 35–72 % (Ostroff et al. 2013).
These data may help in describing the typical cancer 
patient who continue smoking after the diagnosis. Duffy 
et  al. (2012) describe this patient as a heavy smoker 
(with a mean consumption of 28 cigarettes per day for 
35–40 years) with a high level of nicotine addiction with 
a history of failed quitting attempts and some smoking-
related pathological condition. Even when these patients 
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decide to attempt to stop smoking, the success rate is 
generally low. For instance, Walker et al. (2006) showed 
that lung cancer patients start smoking again only 
2 months after the surgery, supporting the idea that this 
population is particularly challenging for smoking cessa-
tion specialists (Park et al. 2011).
Since, heavy smoking (smoking more than 20 cigarettes 
a day, even though different definitions are present in lit-
erature; Husten 2009) and smoking related diseases are 
particularly associated with lung and oral cavity cancer 
(Gandini et al. 2008), we may expect to find more patients 
who continue smoking after diagnosis in these pathologi-
cal conditions. Actually, several studies of non–small-cell 
lung cancer patients have shown that many patients con-
tinue smoking (Gritz 1991; Dresler et al. 1996; Sanderson-
Cox et al. 2002) with estimates ranging from 13 to 70 %.
In particular, Walker et  al. (2004) in a retrospective 
study of 49 lung cancer patients reported that patients 
who were younger and less educated were more likely to 
return to smoking after surgery. They also found a cor-
relation of relapse with depression and social support. 
Authors suggested that patients stop smoking imme-
diately before and after surgery, but relapse to smoking 
remains a problem.
Cooley et  al. (2009) in a study on a sample of 94 
patients with early stage non-small cells lung cancer 
reported similar results, but they also found a correlation 
between smoking and pain. Authors collected data at 1, 2 
and 4 months after surgery and their results suggest that 
the presence of pain is significantly correlated with smok-
ing after surgery.
Schnoll et  al. (2005) among 109 lung and head and 
neck cancer patients, showed that continued smoking 
after 3 months post-surgery is associated to low quitting 
motivation and smoking-related beliefs that increase the 
perception of disadvantages of quitting. In fact, in their 
study authors found that patients who continue smoking 
believe that cons of quitting are more than pros. False or 
biased smoking-related beliefs are frequently present in 
smokers. Different studies reported that smokers usually 
show some kind of belief bias, ranging between 20 and 
80 % (Masiero et al. 2015). This is also true in oncology 
settings. Such biased thoughts and beliefs may be exem-
plified by patients developing the idea that the cancer 
does not relate to individual choices and behavior but 
only to uncontrollable factors such as genetic predisposi-
tion, environmental pollution, etc. (Arnett 2000).
In particular, smokers tend to underestimate smoking-
related risks (Borrelli et al. 2010). For instance, a study of 
Bock et al. (2001), reported that 47.6 % of smokers admit-
ted to the emergency department for acute respiratory 
care did not believe that they had a condition that was 
caused or made worse by smoking.
Furthermore, smokers compared with non-smokers 
tend to underestimate risks concerning themselves, but 
they often change their judgment when thinking about 
others’ risks. This attitude is defined optimistic bias 
(Weinstein et al. 2005; Weinstein 1989). It drives people 
to believe that they are protected from the consequences 
of potential sources of risk and reinforces cigarette smok-
ing. However, some authors (e.g. Milbury et  al. 2012; 
Gritz et al. 2005) have suggested that giving up smoking 
may be facilitated if patients become aware of the possi-
bility of changing their behavior and in so doing reduce 
further risks.
Cancer-related emotional distress may favor smoking 
as well. Indeed, depression is often present in patients, 
ranging between 3 and 31 % (Krebber et  al. 2014). Also 
blame contribute to exacerbating patients’ psychologi-
cal distress. Paradoxically, this reaction seems to initiate 
a vicious circle, which reduces the motivation to start an 
antismoking program (e.g. Chapple et al. 2004). A study 
by Shin et al. (2014) on 45 patients and 173 family mem-
bers who continued to smoke for at least 1 month after 
the diagnoses reported interesting data about the emo-
tional experience of patients and their relatives. In this 
study, most smoker patients report to experience guilt 
toward their family (75.6 %) and to conceal their smok-
ing behavior. Similarly, relatives who continue smoking 
feel guilt toward patients (63.6 %). Hence, both relatives 
and patients experience negative emotions and try to 
prevent conflicts hiding their behavior also to the health 
personnel.
Long-term abstinence can be hindered by a negative 
mood, since a correlation between cigarette smoking 
and depression is well established (McClave et al. 2009). 
Depressed smokers or smokers with a previous history 
of major depression generally have a high level of nico-
tine dependence and a low probability of a successfully 
attempt to stop smoking.
In oncology settings, depression is a critical issue for 
patient management. Indeed, cancer patients can expe-
rience high levels of worries, fears, anxiety and nega-
tive emotions related to the disease and its treatment 
(surgery, chemotherapy or radiotherapy, periodic clini-
cal meetings, long periods of hospitalization, tests and 
examinations). Patients may then use cigarette smoking 
as a coping strategy. Furthermore, the pharmacologi-
cal properties of nicotine, with its cognitive-enhancing 
effects, reinforces the perceived valued of cigarettes since 
they may be used to alleviate treatment-related negative 
effects on memory and attention.
Spek et  al. (2013) found that the decrease of self-effi-
cacy tends to negatively affect smokers’ confidence in 
their ability to quit smoking. Actually, patients with 
a high degree of confidence in their power to give up 
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smoking have a higher success rate than smokers with 
a low confidence. Also, they report less relapses after 
an attempt to quit (McBride and Ostroff 2003; Elfeddali 
et al. 2012).
Other context-related variables influence smoking ces-
sation, such as living or working with people who habitu-
ally smoke. Indeed, patients who live with smokers are 
more likely to maintain their habit than are patients who 
live with non-smokers or in a smoke-free home. Fur-
thermore, social and family support (relatives, friends, 
colleagues and so on) can be an important factor in pro-
moting smoking cessation even though different stud-
ies have shown divergent results (Park et al. 2004). May 
and West (2000) in a review of the literature found that 
social support may be beneficial in helping smokers quit-
ting, even if more research is needed to clarify the role 
of relatives, especially in cancer survivors. However, 
Schnoll et al. (2002) in a study of 74 patients found that a 
low readiness to quit smoking after a cancer was strongly 
associated with the fact of having a relative at home who 
smoke. After hospitalization, when the patient goes back 
home, smoking-related cues (e.g. a habitual smoking 
place; smoking-related daily routine; other people who 
smoke; sensorial stimuli and the like) may influence their 
ability to remain abstinent.
This fact has been considered as a serious barrier in 
helping patients to stop smoking. Indeed, daily exposure 
to smoking-related stimuli may produce physiological 
and cognitive changes that favor urgency and craving 
due to a so-called attentional bias. This cognitive bias 
is related to the selective properties of the attention. It 
concerns the attitude of smokers and former smokers to 
orient their attention to tobacco cigarette smoking cues 
(Field et al. 2009) favoring the need to smoke. Finally, Ark 
et al. (1997) found that in head and neck cancer patients 
heavy alcohol use is a negative predictor of smoking 
cessation.
Smoking cessation interventions for cancer patients: state 
of the art
Smoking interventions may be classified into two main 
approaches: smoking cessation aids (SCAs) and cogni-
tive behavioral interventions (CBIs). Both methods are 
used to approach cigarette addiction in healthy adults 
and in cancer patients and they can be used alone or in 
combination. However, most research on smoking cessa-
tion has been carried out on healthy people, while there 
are only a few studies available on cancer patients and on 
survivors (Duffy et al. 2012; see Table 2).
Smoking cessation aids: SCAs
Smoking cessation aids involve three categories of ant-
ismoking strategies: nicotine replacement treatments 
(NRTs), tobacco free cigarettes—(TFC) and medications 
(mainly bupropion and varenicline).
Nicotine replacement treatment is very popular among 
smokers. Generally, a first spontaneous attempt to give 
up involves NRT (where available without a medical pre-
scription). They provide nicotine, stabilizing its level in 
the blood in order to avoid a withdrawal syndrome after 
having stopped smoking. They are available in different 
forms including transdermal nicotine replacement prod-
ucts, patch, gum, lozenge, inhaler, spray and sublingual 
tablets. Commonly, the treatment lasts for 10–12 weeks, 
but it is often prolonged to 6 months. The type of NRTs 
chosen depends on personal preference, but clinical con-
siderations should be issued too.
Two NRT groups, depending on the administration 
method, are usually described. The first group includes 
NRTs that require daily administration, generally based 
on the use of patches. The second group include proto-
cols based on multiple administrations a day, so-called 
short-acting NRT (Nides 2008).
The main aims of NRT are three: craving reduction, 
withdrawal control and abstinence promotion (Stead 
et  al. 2008). A growing body of scientific literature 
stresses that NRT helps patients to give up smoking 
(Fiore et al. 2000). Pharmacological trials in particular 
have shown that the combination of multiple forms of 
NRT improves the interruption success rate (Ferguson 
et  al. 2011) also in medical settings (Hurt et  al. 2009). 
Also, NRTs have few side effects, being the most preva-
lent a transient nausea (Fiore et  al. 2008). Their prin-
cipal weak point is the low compliance, since after a 
short period many people interrupt the smoking cessa-
tion program, believing that they are able to control the 
situation without further help (Balmford et  al. 2011). 
NRT may be successfully used with cancer patients, 
generally in association with some form of counseling 
and/or other pharmacological treatment (see Table 2). 
For instance, a retrospective study by Garces et  al. 
(2004) showed that a combination of NRT and other 
behavioral and pharmacological treatment is as effec-
tive in head and neck cancer patients as in the general 
population.
A particular type of NRT involves tobacco-free ciga-
rettes (TFCs) also called e-cigarettes. These devices have 
rapidly become widespread over the last 5 years, and are 
often used by smokers to reduce the daily number of cig-
arettes, or to smoke in places where tobacco cigarettes 
are not allowed.
A TFC device is composed of a battery-powered device 
that produces a vapour for inhalation. The steam contains 
humectants, flavours, and pure nicotine. Liquids used in 
e-cigarettes do not contain tobacco and do not require 
combustion. They may or may not contain nicotine.
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TFCs containing nicotine can be considered a NRT, 
albeit with specific and distinct characteristics. Firstly, 
comparing TFCs with traditional NRTs, the former 
deliver a modest amount of nicotine (Fagerström and Eis-
senberg 2012). Secondly, TFCs present a better usability 
and they are more appealing for smokers since they can 
be used when needed by a well-known modality, i.e. tak-
ing a cigarette-like device to the mouth and inhaling. In 
doing so, smokers not only may react to an immediate 
need or desire, but they can enact a gesture associated 
with their previous status (cigarette smokers), thus elicit-
ing positive emotions and satisfying psychological expec-
tations. Thirdly, TFCs may be used ad  libitum enabling 
patients to feel free to control their behavior instead of 
feeling an under external imposition. For these reasons, 
it has been suggested that TFCs fit in very well with both 
the psychological and physiological needs of smokers 
who want and/or need to stop.
Some clinical trials revealed that e-cigarettes attenu-
ate the craving for cigarettes (Wagener et  al. 2012; Bul-
len et al. 2013). Furthermore, a recent review of the field 
showed that TFCs may be considered safe, with few 
adverse events and limited toxicity (Farsalinos and Polosa 
2014). In the general population, nicotine TFCs has been 
showed to be more efficacious in reducing withdrawal 
symptoms than nicotine-free TFCs (Etter and Bullen 
2011). However, also the latter may be considered valid 
options in oncology settings when supported by coun-
selling, as shown by ongoing studies (Cipolla 2012; Luc-
chiari et  al. 2016). The use of nicotine-free TFCs allow 
drug-free smoking cessation treatments, and this fact 
could be particularly interesting for patients undergo-
ing aggressive therapies or at high risk for cardiovas-
cular events. Though some others studies did not find 
and effect of the use of TFCs in a population of cancer 
patients (e.g. Borderud et  al. 2014; Barton 2015), we 
argue that only long run longitudinal studies on targeted 
population and using randomized design will clarify the 
role of TFCs devices to help patients to quit smoking.
At the time of publishing, there is a clear gap in the 
knowledge about the feasibility, efficacy and safety of 
TFCs in oncology settings. In consideration of the lack 
of evidence, it is not possible to recommend a systematic 
use of TFCs with cancer patients (Cummings et al. 2014). 
However, a number of studies are now open on over the 
world. At our institution, two trials are currently ongoing 
to analyse how TFCs with and without nicotine might be 
included in clinical protocols both during cancer treat-
ments and in early diagnosis screening programs.
Lastly, the pharmacological approach to smoking cessa-
tion is mainly based on two medications: bupropion and 
varenicline, both of which are extensively used in clini-
cal practice. Bupropion is an atypical antidepressant that 
promotes cessation probably by reducing the stimulating 
effect of neurotransmitters, being an inhibitor of dopa-
mine and norepinephrine reuptake. It counteracts crav-
ing and smoke-related withdrawal symptoms (Jorenby 
et  al. 2006). In addition, it counters emotional distress 
during abstinence, which is a very important character-
istic to consider for cancer patients. Indeed, as noted 
above, cancer patients frequently experience high levels 
of depression, and smoking interruption can drastically 
increase this because of psychological and physiological 
cigarette dependence.
Bupropion has been administered to cancer patients 
during treatment, and it was found to improve their 
mood, facilitating the smoking cessation success. In par-
ticular, Schnoll et  al. (2010) designed a double-blind, 
placebo-controlled trial ran on a sample of 246 cancer 
patients (mix cancer sites). In the first arm of the study, 
patients received 5 counseling session, 8  weeks of NRT 
and 9  weeks of bupropion. In the second arm, patients 
received the same treatment of group 1, but bupropion 
was substituted by a placebo. While NRT and counseling 
was found to be effective in non-depressed patients, 
bupropion showed to be beneficial for those patient who 
reported depressive symptoms. Benefits were found both 
for mood and for smoking cessation rate.
Bupropion has other relevant properties, e.g. it reduces 
post-cessation weight gain (Martinez et al. 2009), and it 
can be used even with patients with cardiovascular prob-
lems. However, the use of bupropion should be avoided 
for patients receiving active treatments for brain or other 
central nervous system cancers, and for those patients 
with a history of seizures, bulimia or anorexia nervosa. 
Furthermore, the use of this agent must be carefully 
weighed when dealing those patients receiving chemo-
therapy with direct CNS effects due to the increased 
potential for seizure. More research in the safety of 
bupropion during cancer therapy is warranted, even 
though no further contraindications are suggested (Klo-
sky et al. 2007).
A further pharmacological treatment for smoking 
dependence involves the use of varenicline. This is a 
partial agonist of nicotinic acetylcholine receptor sub-
type α4β2, reducing dopamine stimulation. A study by 
Gonzales et  al. (2006) reported that a 12-weeks vareni-
cline-based treatment counters craving, urgency and 
withdrawal symptoms in healthy smokers. If properly 
administered, varenicline causes cigarettes to lose their 
habitual pleasure, favouring the extinction of the smok-
ing habit (Baraldo et al. 2012; Ebbert et al. 2010). This is 
particularly true for smokers with a low motivation to 
give up and/or with important nicotine withdrawal symp-
toms (Nides 2008). In the general population, varenicline 
is considered the best option to increase the probability 
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of success of a smoking cessation program, reaching a 
25–30  % of abstinences within the first year (Issa et  al. 
2013; Mills et al. 2012). However, a study by Hawari et al. 
on a heterogeneous sample (n = 199) of cancer patients 
(mix cancer sites) failed to find any significant advan-
tage by the use of varenecline in association with NRT at 
3 months with respect to NRT alone.
Nausea, abnormal dreams, upper respiratory tract 
infection and insomnia are the most commonly reported 
adverse events, and these are generally mild and self-lim-
iting. Although it has been associated with depression, 
suicidal behaviour and myocardial infarction (depres-
sion is actually a relative contra-indication; Brophy 2011), 
a recent meta-analysis showed that there is no clear 
evidence that these side-effects are causally related to 
the drug use (Prochaska and Hilton 2012). Varenicline 
should be avoided with pregnant, nursing, in patients 
with renal impairment or patients younger than 18, but 
generally appears safe in treating tobacco dependence 
of patients with cancer. Furthermore, the use of vareni-
cline seem to support cognitive functions (Clinical Prac-
tice Guidelines in Oncology: Smoking Cessation 2015). 
In particular, a recent study by Price et  al. (2016) on a 
sample of 132 smokers with a diagnosis of cancer found 
that varenicline was well tolerated by patients. They 
designed a two arms randomized study. Patients received 
or 12 weeks of varenicline followed by 12 weeks of pla-
cebo or a full 24  weeks of varenicline. However, at the 
moment of publication only data about the first 12 weeks 
of varenicline are available. The pharmacological treat-
ment was combined with five standardized brief smoking 
cessation counselling sessions. About 40.1 % of smokers 
stopped after 12  weeks of treatment, a datum compa-
rable with results found in the general population. Side 
effects symptoms were present (in particular, nausea and 
sleep problems) but they did not prevent patients to com-
plete the treatment. Furthermore, abstainers at 12 week 
showed a significant decrease in cognitive deficits. The 
authors did not report data about longer-term assess-
ment points and the placebo condition. Furthermore, the 
cancer stage is very heterogeneous (in the 33.3 % is not 
specified) and many patients (25.8  %) are in remission. 
Under this condition is difficult to evaluate the real ability 
of patient to tolerate the treatment side effects.
The use of vareniclin in oncological setting require 
more research in order to establish in which context it 
should be beneficial.
Cognitive behavioral interventions (CBIs)
Cognitive behavioral interventions (CBIs) are based on a 
psychological approach to smoking aimed at supporting 
people in changing their behavior by a cognitive restruc-
turing. Low-intensity or high-intensity interventions may 
be used. The low-intensity interventions are more fre-
quently used in oncology settings, in screening programs 
as well as in other clinical settings. They are character-
ized by self-help tools and the use of so-called minimal 
advice. Normally, the self-help tools are booklets, bro-
chures, and informative paper-based support materials, 
although video clips and computer-based tools are also 
now available. These tools convey general information 
about the consequences of smoking and the benefits of 
giving up.
The main advantage of self-help tools is that they target 
a large population; unfortunately, their effects are gener-
ally poor (Lancaster and Stead 2005).
The minimal advice is a short list of recommenda-
tions, requiring just some minutes, focused on why it 
is important to consider to stop smoking and how (and 
where) it is possible to address the issue, e.g. starting an 
antismoking program. This approach is particularly use-
ful in a clinical setting, where trust between patients and 
physicians is already established and where external but 
affordable resources are available (e.g. an antismoking 
center).
When meeting a patient, oncologists and/or nurses 
may merely explain the importance of interruption of 
smoking in cancer care and the impact on treatment, 
but they do not directly suggest strategies or therapies 
(Emmons et al. 2013).
The minimal advice consists of the evaluation of the 
personal smoking history and a few suggestions. Sev-
eral studies reported a delay of specific interventions for 
patients who smoke after the diagnosis, probably due to 
a “beating the disease” priority. The urgency of the dis-
ease focuses the doctor’s attention on the assessment and 
the cure of clinical conditions, while other aspects may 
go untreated.
The high intensity interventions involves a counseling 
approach. Behavioral counseling has been defined as a 
relationship between an expert and a client, focused on 
behavior to be changed. Normally, each session lasts 
15–30 min.
A broadly used tool is the motivational interview aimed 
to understand the subjects position within the so-called 
cognitive spiral of change (Prochaska and DiClemente 
1983), and to activate motivational drivers. Previous 
research has stressed that a high motivational level can 
facilitate smoking cessation and abstinence, while a low 
motivational level negatively affects the success rate. The 
motivational level is considered as a benchmark to decide 
which strategy to opt for.
Behavioral counseling can be used in oncology settings 
and continued during the follow-up scheduling. Gener-
ally speaking, behavioral counseling starts during the 
hospitalization and should be continued after discharge. 
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It has been shown that it increases the giving-up rate 
after 6 and 12  months (Rigotti et  al. 2008) in hospital-
ized patiens. Another widespread model, very useful in 
hospital settings, is telephone counseling. Habitually, it 
is used in combination with traditional (on-site) coun-
seling (Stead et al. 2006). This intervention can be proac-
tive or reactive (Lichtenstein et  al. 1996). The proactive 
approach targets patients already prompted to give up, 
and then may be used to monitor the ongoing situation 
over time. Instead, the reactive approach is based on spe-
cific needs of patients (Stead et  al. 2008). A review on 
telephone counselling has stressed that it sustains absti-
nence in the long run (Tzelepis et  al. 2011). The smok-
ing cessation counseling should be accompanied by a set 
of recommendations regarding the need of a general-
ized lifestyle change (Anderson et  al. 2002). This aspect 
of counseling could be very important in oncology set-
ting, since physical activity may have a positive impact on 
quality of life and wellbeing (Gill et al. 2013), thus poten-
tially acting as the trigger of a virtuous circle. Health 
personnel could use their privileged role to encourage 
changes in this direction and redirect patients to exter-
nal services after discharge. Generally, speaking coun-
seling may be considered effective in supporting smoking 
attempts in oncology settings in association with smok-
ing cessation aids (Klemp et al. 2016). For instance, Park 
et al. (2011) studied the effect of antismoking counselling 
in association with a pharmacological tobacco treatment 
(Varenicline) in a sample of 49 cancer patients with a 
thoracic cancer, showing the positive impact of this com-
bined treatment. In this study, the intervention consisted 
in a 12-week program (Varenicline and counseling). 
Patients in the treatment group received a median of 9 
counseling sessions structured according the 5 As brief 
counseling model (Ask, Advise, Assess, Assist, Arrange 
follow up). Authors report that the prevalence abstinence 
rate at 12  week follow-up was 40.6 in the intervention 
group and 14.3 in the control group.
Similar results were obtained by de Bruin-Visser et al. 
(2012) using a 1-year minimal intervention counseling 
program delivered by nurses (one visit a week in the first 
month and one every other month with the endpoint at 
12 months). Authors included in their study 145 patients 
with mix cancer sites and found a positive effect of the 
counseling, since at 6  months the 40  % of patients had 
stopped smoking, and 33 % was abstinent at 12 months. 
During this period, most patients also use some kind of 
nicotine substitutes (83 %), but authors report no associ-
ation between abstinence and the use of nicotine replace-
ment products. However, Bastian et  al. (2013) failed to 
find any positive relationships between a telephone-
based counseling program and smoking cessation in a 
large sample of 596 lung cancer patients. In particular, 
authors compared an at-distance counseling program 
(6 calls) based on motivational interviewing techniques 
with tailored self-directed materials (n   =   245) and a 
minimal intervention based only on tailored self-directed 
materials (n   =   251). In both groups nicotine patches 
was al used if not contraindicated. Their results showed 
no differences between the two groups, even though in 
younger patients (<50) the abstinence rate was higher 
(16 vs. 4 %) at 2 weeks post-surgery. This study underline 
once more that lung cancer patients need intensive inter-
ventions to stop smoking.
Other studies have tested the efficacy of a strategy 
based on a brief physician intervention, showing that 
low intensity intervention have poor power in helping 
patients quitting attempts. In particular, Schnoll et  al. 
(2003) compared two large groups of patients (mix can-
cer sites). The intervention group (n  =  217) received 
a minimal advise and information about the benefits of 
quitting and smoking cessation treatment. Furthermore, 
patients in this group received a self-help smoking ces-
sation guide a telephone line for additional assistance or 
information. The control group (n =  218) received only 
a minimal advise about smoking by their physician. At 
6 months, 14.4 % patients in group 1 and 11.9 % in group 
2 had stopped smoking, showing no significant differ-
ences between the two arms of the study.
Though the studies we have considered did not directly 
analyzed the cost-effectiveness of smoking cessation 
treatment in oncology settings, de Bruin-Visser et  al. 
(2012) suggest to estimate cost-effective analysis for can-
cer patients using by studies in the general population. In 
particular, Song et  al. (2002) found that NRT for smok-
ing cessation is cost-effective. The results of the deci-
sion analyses indicated that, as compared with advice 
or counseling alone, the incremental cost per life-years 
saved is about $1441–$3455 for NRT, $920–$2150 for 
bupropion, and $1282–$2836 for NRT plus bupropion. 
The cost-effectiveness of adding NRT and bupropion to 
advice or counseling for smoking cessation is better than 
many other accepted health care interventions. Hoogen-
doorn et  al. (2010) analyzed the long-term cost-effec-
tiveness in patients with chronic obstructive pulmonary. 
They reported that pharmacological treatments in com-
bination with intensive counselling was cost saving com-
pared with intensive counselling alone, and that the latter 
in turn was more effective than minimal intervention.
Finally, Meenan et al. (1998) analyzed the cost-effective-
ness of a hospital-based smoking cessation intervention 
reporting that the cost of the research intervention was 
$159 per smoker, and incremental cost per incremental 
quit was $3697. Incremental cost per incremental dis-
counted life-year saved ranged between $1691 and $7444, 
much less than most other routine medical procedures.
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Conclusions
A cancer diagnosis may represent a fundamental teach-
able moment for smokers, leading them to give up 
smoking or to significantly reduce daily cigarettes. Most 
former smokers declare that they decided to quit due to 
physical issues or the fear of future health consequences 
of smoking (Gallus et  al. 2013). Furthermore, a regres-
sion analysis on 15,489 smokers participating in lung 
cancer screening studies reviled that smoking cessation 
is strongly associated with screening abnormalities and 
that efficacious smoking cessation programs should be 
integrated within screenings (Tammemägi et  al. 2014). 
Despite this evidence, few studies have directly addressed 
the problem of how to help a patient with cancer to aban-
don unhealthy habits. Additionally, even though some 
recommendations exist, no specific and validated pro-
tocols are recognized as a valid and shared antismoking 
approach in oncology settings. As a consequence of this 
attitude a cancer patient is rarely concretely and system-
atically supported in a smoking cessation journey (e.g. 
Nayan et al. 2011; de Bruin-Visser et al. 2012), with the 
result that though many patients developed a good moti-
vation to stop, few actually remain abstinent in a long 
run. Thus, the emotional trigger of the diagnosis and the 
motivational context of the clinical setting succeed only 
in helping patients to suspend cigarette smoking for a 
short period (e.g. Land et  al. 2011) but not as a sound 
lifestyle change.
From a psychosocial point of view, the fact that motiva-
tion to stop level regresses to its pre-diagnostic level is an 
expected phenomenon (Slovic et al. 2004). Indeed, emo-
tions have a time-limited effect and their impact on deci-
sion-making processes (e.g. whether to attempt quitting 
or not) rapidly fades after an emotional burden. Emotions 
must be considered as short-time cognitive modulators, 
being able to focus attention on risk-related behaviors 
and the need to avoid them in a specific spatial and tem-
poral context (Pravettoni et al. 2012). Consequently, time 
matters, since the more time pass between diagnosis and 
treatments the more the motivation to quit decreases.
Furthermore, in order to help oncology patients to 
reduce smoking-related risks, it is vital to know the gen-
eral characteristics of the context in which the emotions 
arose. If a patient learns in a specific, clinical setting (a 
surgery and/or oncology department) that smoking is 
dangerous and that quitting could be a good solution 
for their future health, this setting will be associated 
with that emotionally-laden knowledge. Consequently, 
patients will develop a situated learning that will moti-
vate their choices. However, when a patient goes back 
home the context will dramatically change, activating 
previous learning and habits, e.g. smoking while watch-
ing TV or after dinner. Here the motivation to quit will 
rapidly vanish if not adequately supported by prior inter-
ventions and adequately sustained by a continuous help, 
e.g.by a telephone counseling. Actually, in a study on 721 
lung cancer survivors, smoking cessation success was 
found to be negatively associated with smoking exposure 
at home (Eng et al. 2014).
Consequently, we argue that in order to help patients 
to give up smoking, the health personnel working in 
oncology settings should be prepared to offer a com-
plete program aimed at promoting health by integrating 
new perspectives and attitudes in patients’ values sys-
tem. Cancer centers should promote smoking cessation 
applying guidelines and doing more research on smokers’ 
needs in order to implement tailored and effective inter-
ventions (Mazza et al. 2010; Cataldo et al. 2010).
In particular, even if it is very important to consider 
the cancer treatment a teachable moment to help a con-
crete lifestyle change, we claim that emotions should not 
be used as levers to force their change, but only as initial 
triggers. Indeed a social-cognitive approach to patients 
suggests that physicians and nurses should use their posi-
tion within the clinical setting to drive patients through 
a sound learning process, instead of causing just a time-
limited suspension of a dysfunctional behavior. In par-
ticular, a cognitive perspective should be used in order to 
understand which personal beliefs sustain the smoking 
behavior, since biased evaluations could prevent patients 
success in their attempts to quit (Masiero et  al. 2015; 
Pepper et  al. 2014). However, to achieve this aim the 
hospital personnel should be educated by specific train-
ing and motivated to adopt the best practices by hospital 
initiatives.
Overcoming the limits of the classical minimal advice 
approach, which could be just the initial part of a more com-
plex process, the social-cognitive intervention should be:
  • Integrated the smoking cessation treatment should 
be experienced as an integral part of the cancer man-
agement. In particular, nurses could serve this aim by 
introducing the issues of smoking and smoking cessa-
tion and by evaluating the tobacco dependence and the 
motivation to stop so to address patients to dedicated 
services.
  • Personalized the therapeutic options provided to 
patients should be compatible with their values, needs 
and attitudes. Furthermore, it should address a whole 
lifestyle change.
  • Proactive offering patients continuity in treatments, 
avoiding offering merely on-demand support or sugges-
tions.
  • Reactive providing patients dedicated treatments or 
support when needed, independently of any therapeutic 
scheme.
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This approach requires a multidisciplinary effort since 
physicians, nurses and behavior change specialist should 
work together each having specific roles (Lucchiari et al. 
2013). In particular, physicians should introduce the issue 
of smoking within the general treatment, using the ther-
apeutic alliance to gain the attention of the patient and 
guide the subsequent cognitive assessment of smoking-
related risks and benefits of quitting. Some studies (e.g. 
Mazza et  al. 2010) have reported the fear of physicians 
to suggest antismoking programs due to the fragile emo-
tional situation of patients, and the potential to cause 
distress responses. Nonetheless, an antismoking path-
way should not be experienced by patients as a further 
stressor, and we suggest that health personnel could play 
a vital role in helping patients to approach the problem in 
a balanced fashion, to reduce stress and maximize bene-
fits. Since a number of studies on cancer patients demon-
strate moderate smoking cessation success following the 
general principles of evidence-based smoking cessation 
protocol (Gritz et  al. 2014) a targeted and interdiscipli-
nary approach should be adopted using systematic moni-
toring of patients’ needs and behavior in order to sustain 
long-term abstinence (Hawari et  al. 2013). However, 
when this is not possible, physicians and nurses should 
act as valuable information carriers, addressing relevant 
issues and encouraging patients to search for support in 
external services.
Health personnel should provide detailed informa-
tion about smoking hazards (both before, during and 
after cancer) and support patients’ motivation to start an 
attempt to quit (Zwar et  al. 2011). This support should 
be based on a social-cognitive perspective, since any 
information and/or advice provided should be aimed at 
breaking down false beliefs and cognitive biases and at 
reinforcing the emotional, physical and social benefits 
of the change. Consequently, personnel should be well 
trained in performing this task and they should be aware 
of the important role they are playing in the whole pro-
cess. This mean that physicians and nurses are regarded 
not only as information bearers, but also as change 
facilitators, potentially making a great difference in the 
result (Cooley et  al. 2008). Finally, specialized counse-
lors should follow the entire clinical pathway by regular 
meeting (potentially also at a distance, e.g. by telephone) 
to provide emotional support, sustain motivation, and 
approach specific concerns. This should also include 
behavioral interventions (e.g. helping patients to manage 
anxiety states, sleep disturbances and the like).
Physicians, nurses and specialists must therefore work 
in an integrated fashion, able to exchange informa-
tion, keep track of the patients’ history and adequately 
respond to patients’ demands throughout all the oncol-
ogy treatment. This also means that when patients need 
help, e.g. in the use of antismoking medications or in 
following specific procedures, they can easily find prac-
tical support, as some studies have shown that patients 
often fail to continue the antismoking treatment due 
to practical problems (e.g. McBride and Ostroff 2003). 
Indeed, a whole and integrated approach will get patients 
into a protection context, where emotional, behavioral 
and practical issues are continually monitored and sup-
ported. However, the future success of tobacco smoking 
programs in oncology settings will depend on the level of 
knowledge education and motivation of health personnel.
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